Investment In Blood

"In this follow-up to his much-praised book Losing Small Wars: British Military Failure in Iraq and Afghanistan, Frank Ledwidge argues that Britain has paid a heavy cost - both financially and in human terms - for its involvement in the Afghanistan war. Ledwidge calculates the high price paid by British soldiers and their families, taxpayers in the United Kingdom, and, most importantly, Afghan citizens, highlighting the thousands of deaths and injuries, the enormous amount of money spent bolstering a corrupt Afghan government, and the long-term damage done to the British military's international reputation. In this hard-hitting exposé, based on interviews, rigorous on-the-ground research, and official information obtained through the Freedom of Information Act, Ledwidge demonstrates the folly of Britain's extended participation in an unwinnable war. Arguing that the only true beneficiaries of the conflict are development consultants, international arms dealers, and Afghan drug kingpins, he provides a powerful, eye-opening, and often heartbreaking account of military adventurism gone horribly wrong."--

The authors discuss a new way of judging and interpreting global events as the necessary context of investment strategy

NATIONAL BESTSELLER • The gripping story of Elizabeth Holmes and Theranos—one of the biggest corporate frauds in history—a tale of ambition and hubris set amid the bold promises of Silicon Valley, rigorously reported by the prize-winning journalist. With a new Afterword covering her trial and sentencing, bringing the story to a close. “Chilling ... Reads like a thriller ... Carreyrou tells [the Theranos story] virtually to perfection.” —The New York Times Book Review In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the next Steve Jobs: a brilliant Stanford dropout whose startup “unicorn” promised to revolutionize the medical industry with its breakthrough device, which performed the whole range of laboratory tests from a single drop of blood. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes’s worth at an estimated $4.5 billion. There was just one problem: The technology didn’t work. Erroneous results put patients in danger, leading to misdiagnoses and unnecessary treatments. All the while, Holmes and her partner, Sunny Balwani, worked to silence anyone who voiced misgivings—from journalists to their own employees.

Blood on the Street is a riveting account of the Wall Street scam in which ordinary investors lost literally billions of dollars -- in many cases their life savings -- in one of the greatest deceptions ever, by the crack reporter who broke the original story. In one of the most outrageous examples of dirty dealing in the history of Wall Street, hundreds of millions of dollars in illicit profits were made during the booming 1990s as a result of research analysts issuing positive stock ratings on companies that kicked back investment banking business. Now, for the first time, award-winning journalist Charles Gasparino reveals the whole fascinating story of greed, arrogance, and corruption. It was Gasparino's front-page reporting in The Wall Street Journal that brought the story to national attention and spurred New York State attorney general Eliot Spitzer to launch an official probe. Now, Gasparino goes behind his own headlines to tell the inside story of this spectacular swindle -- with revelations from his unprecedented access to never-before-published depositions and documents, including e-mail exchanges leading all the way up to Citigroup CEO Sanford Weill. Drawing on his research and interviews with industry insiders, Gasparino takes readers into the back rooms of Wall Street's top investment firms and captures the outsize personalities of three key players: Salomon Smith Barney's Jack Grubman, a braggart with one of the largest salaries on Wall Street; Merrill Lynch's Henry Blodget, the Yale graduate who hyped his way to the top of the research pyramid; and Morgan Stanley's Mary Meeker, the "Queen of the Internet," who foresaw the market catastrophe but gave in to the pressures Blood on the Street shows how regulators, like former SEC chairman Arthur Levitt, allowed the deceptive practices to fester and grow during the 1990s bubble, leaving the door open for a then- little-known attorney general from New York State to step in and make his mark by holding Wall Street accountable. Gasparino provides the first major account of Spitzer's rise to prominence, detailing how the attorney general pursued key players to build his case against Wall Street, including his shifting allegiance to the powerful New York Stock Exchange chairman Richard Grasso. A fast-paced narrative rich in sharp insights, Blood on the Street is the definitive book on the financial debacle that affected millions of Americans.

"Blood transfusion is a life-saving intervention that has an essential role in patient management within health care systems. All Member States of the World Health Organization (WHO) endorsed World Health Assembly resolutions WHA28.72 (1) in 1975 and WHA58.13 (2) in 2005. These commit them to the provision of adequate supplies of safe blood and blood products that are accessible to all patients who require transfusion either to save their lives or promote their continuing or improving health." --Preface.

"The presence, or absence, of neglected tropical diseases (NTDs) can be seen as a proxy for poverty and for the success of interventions aimed at reducing poverty. Today, coverage of the public-health interventions recommended by the World Health Organization (WHO) against NTDs may be interpreted as a proxy for universal health coverage and shared prosperity - in short, a proxy for coverage against neglect. As the world's focus shifts from development to sustainable development, from poverty eradication to shared prosperity, and from disease-specific goals to universal health coverage, control of NTDs will assume an important role towards the target of achieving universal health coverage, including individual financial risk protection. Success in overcoming NTDs is a "litmus test" for universal health coverage against NTDs in endemic countries. The first WHO report on NTDs (2010) set the scene by presenting the evidence for how these interventions had produced results. The second report (2013) assessed the progress made in deploying them and detailed the obstacles to their implementation. This third report analyses for the first time the investments needed to achieve the scale up of implementation required to achieve the targets of the WHO Roadmap on NTDs and universal coverage against NTDs. INVESTING TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES presents an investment strategy for NTDs and analyses the specific investment case for prevention, control, elimination and eradication of 12 of the 17 NTDs. Such an analysis is justified following the adoption by the Sixty-sixth World Health Assembly in 2013 of resolution WHA6612 on neglected tropical diseases, which called for sufficient and predictable funding to achieve the Roadmap's targets and sustain control efforts. The report cautions, however, that it is wise investment and not investment alone that will yield success. The report registers progress and challenges and signals those that lie ahead. Climate change is expected to increase the spread of several vector-borne NTDs, notably dengue, transmission of which is directly influenced by temperature, rainfall, relative humidity and climate variability primarily through their effects on the vector. Investments in vector-borne diseases will avoid the potentially catastrophic expenditures associated with their control. The presence of NTDs will thereby signal an early warning system for climate-sensitive diseases. The ultimate goal is to deliver enhanced and equitable interventions to the most marginalized populations in the context of a changing public-health and investment landscape to ensure that all peoples affected by NTDs have an opportunity to lead healthier and wealthier lives."--Publisher's description.

The untold history of the multiracial making of the border between Canada and the United States. Often described as the longest undefended border in the world, the Canada-US border was born in blood, conflict, and uncertainty. At the end of the American Revolution, Britain and the United States imagined a future for each of their nations that stretched across a continent. They signed treaties with one another dividing lands neither country could map, much less control. A century and a half later, Canada and the United States had largely fulfilled those earlier ambitions. Both countries had built nations that stretched from the Atlantic to the Pacific and had made an expansive international border that restricted movement. The vision that seemed so clear in the minds of diplomats and politicians never behaved as such on the ground. Both countries built their border across Indigenous lands using hunger, violence, and coercion to displace existing communities and to disrupt their ideas of territory and belonging. The border's length undermined each nation's attempts at control. Unable to prevent movement at the border's physical location for over a century, Canada and the United States instead found ways to project fear across international lines They aimed to stop journeys before they even began.

An eye-opening exploration of blood, the lifegiving substance with the power of taboo, the value of diamonds and the promise of breakthrough science Blood carries life, yet the sight of it makes people faint. It is a waste product and a commodity pricier than oil. It can save lives and transmit deadly infections. Each one of us has roughly nine pints of it, yet many don’t even know their own blood type. And for all its ubiquitousness, the few tablespoons of blood discharged by 800 million women are still regarded as taboo: menstruation is perhaps the single most demonized biological event. Rose George, author of The Big Necessity, is renowned for her intrepid work on topics that are invisible but vitally important. In Nine Pints, she takes us from ancient practices of bloodletting to the breakthough of the "liquid biopsy," which promises to diagnose cancer and other diseases with a simple blood test. She introduces Janet Vaughan, who set up the world’s first system of mass blood donation during the Blitz, and Arunachalam Muruganantham, known as “Menstrual Man” for his work on sanitary pads for developing countries. She probes the lucrative business of plasma transfusions, in which the US is known as the “OPEC of plasma.” And she looks to the future, as researchers seek to bring synthetic blood to a hospital near you. Spanning science and politics, stories and global epidemics, Nine Pints reveals our life's blood in an entirely new light. Nine Pints was named one of Bill Gates recommended summer reading titles for 2019.